When survival (Fig 6E) (Median survival: Female untreated: 31 days; Male untreated: 31 days; Female anti-PD1: 34 days; Male anti-PD1:29.5 days, Female CpG: not reached; Male CpG: not reached) and tumor size (Fig 6F–6K) were analyzed separately for each sex, a clear response of increased survival benefit (p = 0.05) (Fig 6E) and decreased tumor growth in CpG 1688 treated females (p = 0.026) (Fig 6K), but not males, was observed. The gene discussed is PDCD1; the disease is neoplasm.